Literature DB >> 15355759

Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments.

Thomas W McAllister1, Tim A Ahles, Andrew J Saykin, Robert J Ferguson, Brenna C McDonald, Lionel D Lewis, Laura A Flashman, C Harker Rhodes.   

Abstract

Increasing evidence suggests that systemic cancer chemotherapy can have significant long-term effects on cognition, particularly on verbal learning, memory, attention, and speed of information processing. These deficits can be a source of significant distress to survivors. There is much less known about the mechanisms, predisposing vulnerabilities, and treatment of these deficits. We will summarize current knowledge of chemotherapy-associated cognitive deficits. Emerging theories about the role of selected genetic polymorphisms in heightening the vulnerability to chemotherapy-induced cognitive decline will be described.

Entities:  

Mesh:

Year:  2004        PMID: 15355759     DOI: 10.1007/s11920-004-0023-y

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  75 in total

1.  Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.

Authors:  Tim A Ahles; Andrew J Saykin; Charlotte T Furstenberg; Bernard Cole; Leila A Mott; Karen Skalla; Marie B Whedon; Sarah Bivens; Tara Mitchell; E Robert Greenberg; Peter M Silberfarb
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

Review 2.  Neurological complications of radiotherapy and chemotherapy.

Authors:  F Keime-Guibert; M Napolitano; J Y Delattre
Journal:  J Neurol       Date:  1998-11       Impact factor: 4.849

Review 3.  Attentional processes and their remediation in children treated for cancer: a literature review and the development of a therapeutic approach.

Authors:  Robert W Butler; Donna R Copeland
Journal:  J Int Neuropsychol Soc       Date:  2002-01       Impact factor: 2.892

Review 4.  Prefrontal neurons and the genetics of schizophrenia.

Authors:  D R Weinberger; M F Egan; A Bertolino; J H Callicott; V S Mattay; B K Lipska; K F Berman; T E Goldberg
Journal:  Biol Psychiatry       Date:  2001-12-01       Impact factor: 13.382

5.  Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease.

Authors:  Richard E Hartman; Helmut Laurer; Luca Longhi; Kelly R Bales; Steven M Paul; Tracy K McIntosh; David M Holtzman
Journal:  J Neurosci       Date:  2002-12-01       Impact factor: 6.167

Review 6.  Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver.

Authors:  P J Meier; U Eckhardt; A Schroeder; B Hagenbuch; B Stieger
Journal:  Hepatology       Date:  1997-12       Impact factor: 17.425

7.  The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function.

Authors:  Michael F Egan; Masami Kojima; Joseph H Callicott; Terry E Goldberg; Bhaskar S Kolachana; Alessandro Bertolino; Eugene Zaitsev; Bert Gold; David Goldman; Michael Dean; Bai Lu; Daniel R Weinberger
Journal:  Cell       Date:  2003-01-24       Impact factor: 41.582

8.  The C270T polymorphism of the brain-derived neurotrophic factor gene is associated with schizophrenia.

Authors:  György Szekeres; Anna Juhász; Agnes Rimanóczy; Szabolcs Kéri; Zoltán Janka
Journal:  Schizophr Res       Date:  2003-12-01       Impact factor: 4.939

9.  APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss.

Authors:  S M Laws; R M Clarnette; K Taddei; G Martins; A Paton; J Hallmayer; O P Almeida; D M Groth; S E Gandy; H Förstl; R N Martins
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

10.  Identification of brain-derived neurotrophic factor promoter regions mediating tissue-specific, axotomy-, and neuronal activity-induced expression in transgenic mice.

Authors:  T Timmusk; U Lendahl; H Funakoshi; E Arenas; H Persson; M Metsis
Journal:  J Cell Biol       Date:  1995-01       Impact factor: 10.539

View more
  20 in total

Review 1.  Candidate mechanisms for chemotherapy-induced cognitive changes.

Authors:  Tim A Ahles; Andrew J Saykin
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

2.  Cancer chemotherapy impairs contextual but not cue-specific fear memory.

Authors:  Jill E Macleod; Joyce A DeLeo; William F Hickey; Tim A Ahles; Andrew J Saykin; David J Bucci
Journal:  Behav Brain Res       Date:  2007-04-19       Impact factor: 3.332

3.  Smaller white-matter volumes are associated with larger deficits in attention and learning among long-term survivors of acute lymphoblastic leukemia.

Authors:  Wilburn E Reddick; Zuyao Y Shan; John O Glass; Susan Helton; Xiaoping Xiong; Shengjie Wu; Melanie J Bonner; Scott C Howard; Robbin Christensen; Raja B Khan; Ching-Hon Pui; Raymond K Mulhern
Journal:  Cancer       Date:  2006-02-15       Impact factor: 6.860

Review 4.  An update on cancer- and chemotherapy-related cognitive dysfunction: current status.

Authors:  Michelle C Janelsins; Sadhna Kohli; Supriya G Mohile; Kenneth Usuki; Tim A Ahles; Gary R Morrow
Journal:  Semin Oncol       Date:  2011-06       Impact factor: 4.929

Review 5.  Genetic Modulation of Neurocognitive Development in Cancer Patients throughout the Lifespan: a Systematic Review.

Authors:  Charlotte Sleurs; Aline Madoe; Lieven Lagae; Sandra Jacobs; Sabine Deprez; Jurgen Lemiere; Anne Uyttebroeck
Journal:  Neuropsychol Rev       Date:  2019-03-30       Impact factor: 7.444

6.  Apoptosis prediction via inhibition of AKT signaling pathway by neogrifolin.

Authors:  Yang Chen; Guo-Fang Peng; Xiang-Zhen Han; Wei Wang; Guo-Qiang Zhang; Xiao Li
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

7.  HIF-1α induced by β-elemene protects human osteosarcoma cells from undergoing apoptosis.

Authors:  Dan Liang; Maowei Yang; Baolei Guo; Lei Yang; Junjun Cao; Xiuli Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-27       Impact factor: 4.553

Review 8.  Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors.

Authors:  Jeanne S Mandelblatt; Paul B Jacobsen; Tim Ahles
Journal:  J Clin Oncol       Date:  2014-07-28       Impact factor: 44.544

Review 9.  Neurocognitive functioning and genetic variation in patients with primary brain tumours.

Authors:  Jeffrey S Wefel; Kyle R Noll; Michael E Scheurer
Journal:  Lancet Oncol       Date:  2016-03-02       Impact factor: 41.316

10.  Neuroimaging biomarkers and cognitive function in non-CNS cancer and its treatment: current status and recommendations for future research.

Authors:  Andrew J Saykin; Michiel B de Ruiter; Brenna C McDonald; Sabine Deprez; Daniel H S Silverman
Journal:  Brain Imaging Behav       Date:  2013-12       Impact factor: 3.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.